Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Protalix BioTherapeutics's EBIT per Share for the
three
months ended in Jun. 2026 was $0.07.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.30.
During the past 12 months, the average EBIT per Share Growth Rate of Protalix BioTherapeutics was 257.70% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 36.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Protalix BioTherapeutics's EBIT per Share or its related term are showing as below:
PLX'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -98.7 Med: 10.9 Max: 52.6
Current: 36.1
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Protalix BioTherapeutics was 52.60% per year. The lowest was -98.70% per year. And the median was 10.90% per year.
PLX's 3-Year EBIT Growth Rate is ranked better than 75.88% of 1169
companies
in the Biotechnology industry
Industry Median: 15.4
vs PLX: 36.10
Protalix BioTherapeutics (AMEX:PLX) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Protalix BioTherapeutics EBIT per Share Related Terms
Protalix BioTherapeutics EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.30
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protalix BioTherapeutics (PLX) has a EBIT per Share of $0.30 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Protalix BioTherapeutics and its competitors. According to the industry distribution chart, Protalix BioTherapeutics ranks #282 out of 1169 companies in the Biotechnology industry, placing it in the top 24.1%.
Is Protalix BioTherapeutics' EBIT per Share too high?
Protalix BioTherapeutics' current EBIT per Share is $0.30. The Biotechnology industry median EBIT per Share is 15.40. Protalix BioTherapeutics' value of $0.30 is 98.1% below this industry median. Based on the distribution chart, Protalix BioTherapeutics ranks #282 out of 1169 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Protalix BioTherapeutics has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Protalix BioTherapeutics' EBIT per Share compare to GLSI and DTIL?
According to the Biotechnology industry distribution chart, Protalix BioTherapeutics ranks #282 out of 1169 companies for EBIT per Share. This places Protalix BioTherapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 15.40. Protalix BioTherapeutics' value of $0.30 is 98.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,169 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Protalix BioTherapeutics's current EBIT per Share of $0.30 is 98.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Protalix BioTherapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Protalix BioTherapeutics's current EBIT per Share is $0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protalix BioTherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Protalix BioTherapeutics (PLX) is currently considered Fairly Valued. The stock's GF Value™ is $2.20, compared to a current price of $2.34 — trading 6.4% above its estimated fair value. The current EBIT per Share is $0.30 and 98.1% below the Biotechnology industry median of 15.40. Protalix BioTherapeutics' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Protalix BioTherapeutics (PLX), the current EBIT per Share is $0.30 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Protalix BioTherapeutics (PLX) Overvalued in 2026?
Based on GuruFocus' analysis, Protalix BioTherapeutics stock appears to be overvalued.
The current stock price of $2.34 is trading 6.4% above its estimated GF Value™ of $2.20.
GuruFocus considers Protalix BioTherapeutics to be Fairly Valued.
Key valuation signals for PLX:
EBIT per Share: $0.30
GF Value™: $2.20 vs. price of $2.34 (6.4% above fair value)
Industry Position: 98.1% below the Biotechnology median (#282 of 1169)
No single metric tells the full story. See the PLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
54GF Score
Get the complete analysis for PLX
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLX has been successfully added to your 
